Xenon Pharmaceuticals Inc.

Wisconsin Alumni Research Foundation

The University of British Columbia

Alison J Brownlie

Michael R Hayden

Alan D Attie

Mark Gray-Keller

James M Ntambi

Makoto Miyazaki

Mark P Gray-Keller

The use of screening assays based on the role of human stearoyl-CoA desaturase-1 ('hSCD1') in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.

Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents

A cDNA encoding a novel human stearoy-CoA desaturase (dubbed 'hSCD5') as well as vectors and cells comprising such polynucleotide are disclosed. Also described are assay methods for determining the ability of small molecules and other chemical agents to increase or decrease he enzymatic activity and/or gene expression level of hSCD5 as well as processes for using such agents to treat, prevent or diagnose a variety of diseases and other conditions.

Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5

A cDNA encoding a novel human stearoy-CoA desaturase (dubbed 'hSCD5') as well as vectors and cells comprising such polynucleotide are disclosed. Also described are assay methods for determining the ability of small molecules and other chemical agents to increase or decrease the enzymatic activity and/or gene expression level of hSCD5 as well as processes for using such agents to treat, prevent or diagnose a variety of diseases and other conditions.

Growing community of inventors

Vancouver, Canada

Alison J Brownlie